Chris Teale

Founder

Chris’s career began in operational research in the mining and chemical industries before moving into healthcare. Between 1987 and 2011 he developed extensive practical and academic experience within the pharmaceutical industry, across both Marketing and R&D.  

Since 2012 he has worked in  Pharmaceutical Consultancy (BridgeheadInternational, GfK, and Ipsos)  

In his industry career, he held leadership positions at both Global and European levels, having been Director of Global Pricing and     Market Access (Oncology) at Astra Zeneca, Director Health Economics, Pricing, Reimbursement and Access at Allergan, Commercial Planning Manager at Fisons, and Portfolio Planning Manager at Novartis in Switzerland.

In his market access roles, he developed global pricing and market access strategies for a wide range of products and therapy areas including personalised healthcare products (requiring both pharmaceutical and diagnostic reimbursement).

He also led “Innovate for Access” programmes which identified creative and innovative approaches to overcoming market access hurdles. In his planning roles, he established middle and long-range forecasting models to support the evaluation of in-license and out-license and other business development opportunities; and models to support resource allocation / optimisation in R&D and Marketing.

Within Ipsos, in addition to being senior vice president market access, Chris led the Autoimmune Centre of Expertise which brought together Real World Data and multi-stakeholder (physician, payer, patient, and policy-maker) insights and behaviours across a broad range of   autoimmune diseases.

Whilst at Ipsos, Chris contributed to the publication of significant thought leadership articles, led global webinars, presented work     at ISPOR, and gave podium presentations in 2021/2/3 at the World Evidence Pricing and Access (EPA) Congress.

A list of his most recent publications can be found further down this page

Chris holds a 1^st class BSc honours degree in     Mathematics from Newcastle University. He also studied at Loughborough University (Management Information Systems) and INSEAD Business School in France (Marketing for International Business).

He is an occasional lecturer on health economics and pharmaceutical pricing and reimbursement at Kings College London and University of California (San Diego), a member of ISPOR     (International Society for Pharmacoeconomics and Outcomes Research) and PMSA (Pharmaceutical Management Science Association).· 

His pro-active membership of both PMSA(Pharmaceutical Management Science Association), with its predominantly US focus, and European ISPOR, with its different payer archetypes, allows TealeHealth to focus on implementation of methodologically rigorous solutions indiverse healthcare systems.
‍